|
Medical and Energy Technologies for the future
|
|
 |
|
Company Background
Aerophase, Inc. is a research and development company in Colorado that is leveraging proprietary aerosol technology for targeted delivery of drugs directly into the lungs. The company is working to commercialize aerosol drug delivery products for the treatment of lung cancer. The next goal is to commercialize the Aerophase aerosol system through preclinical studies, human clinical trials, and FDA approval.
|
Technology
Aerophase’s lead product is an aerosol delivery device that delivers anticancer drugs in aerosol form for treating lung cancer. The lung cancer treatment system is showing substantial delivery and efficacy advantages in preclinical non-small cell lung cancer models. Our unique, patented technology facilitates the inhalation aerosol delivery of anticancer agents into the lungs, uniquely positioning Aerophase for commercial success. The technology uses supercritical CO2 to generate a controlled and reproducible drug aerosol with a median particle size of about 1 µm, which is ideal for particle inhalation. The aerosol facilitates targeted delivery of drugs directly to the tumor sites in the lung. This targeted delivery means that lower doses of drugs are administered, resulting in lower systemic side effects in the body. It has so far been successfully shown that this aerosol system:
• Delivers anticancer agents to the lungs more effectively than other current methods
• Achieves therapeutic concentrations with very low systemic toxicity
• Is uniquely positioned to gain large market share in treatment of the world's most deadly cancer
• Has proven consistent efficacy
• Has been peer-reviewed
The technology is protected with patents and provisional patents.
AEROPHASE IS URGENTLY SEEKING EQUITY INVESTMENT OF UP TO $3 MILLION TO QUALIFY FOR $3 MILLION IN MATCHING FUNDS TO SUPPORT THE FURTHER DEVELOPMENT AND FDA APPROVAL OF THIS TECHNOLOGY.
|
Market Need
There are about 350,000 lung cancer patients in the U.S. Approximately $10 billion is spent each year domestically on lung cancer treatment, with about $800 million spent on mitotic inhibitors such as paclitaxel. The oncology drug market is growing by more than 10% annually. The current route of administration of lung cancer drugs is by IV infusion, which causes side effects throughout the body. New approaches to drug delivery are badly needed. Inhaled oncologic agents represent a new, potentially huge class of therapies for lung cancer, and their anticipated market size is $1 billion per year.
|
Aerosol Delivery Device for Lung Cancer Therapy
|
Additional Company Technologies
Aerophase has focused on the development of technologies that utilize supercritical fluid carbon dioxide as a process fluid. The motivation has been to replace solvents and fluids that are hazardous to health and the environment. Aerophase has successfully developed the following products that use carbon dioxide as a working fluid:
• Metered dose inhalers that use CO2 as a propellant
• A CO2-based cleaning and drying system for the semiconductor industry
• CO2 extraction technologies for drug and energy applications
These technologies are also protected with patents and provisional patents.
|
|
|
|
|
